X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
232 articles about X4 Pharmaceuticals
-
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
11/5/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils.
-
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel
11/4/2019
Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance.
-
X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019
10/25/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that it will report its financial results for the third quarter ended September 30, 2019 before market open on Thursday, November 7, 2019.
-
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients
9/30/2019
X4 Pharmaceuticals, Inc. announced positive results from the Phase 2a portion of its open-label Phase 1/2 clinical trial of mavorixafor in combination with axitinib in patients with advanced clear cell renal cell carcinoma.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sept. 27, 2019
9/27/2019
X4 Pharmaceuticals, Inc. announced that, on September 27, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
BioSpace Movers & Shakers, Sept. 27
9/27/2019
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments. -
X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
9/23/2019
Mr. Aliski has more than two decades of biopharmaceutical executive leadership experience at both public and private companies
-
BioSpace Movers & Shakers, Sept. 20
9/20/2019
Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments. -
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development
9/18/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj, Ph.D., as Senior Vice President, Research and Development.
-
X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences - Sept. 17, 2019
9/17/2019
X4 Pharmaceuticals, Inc. announced that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare Conference.
-
X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress
9/12/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will present clinical data on its lead product candidate, mavorixafor (X4P-001), in combination with Inlyta® (axitinib) at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress, taking place September 27 – October 1 in Barcelona, Spain.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug. 29, 2019
8/29/2019
X4 Pharmaceuticals, Inc. announced that, on August 28, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to two new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/6/2019
X4 Pharmaceuticals, Inc. announced that on August 2, 2019 the Compensation Committee of X4’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,000 shares of its common stock to 4 new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.
-
X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome
7/30/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the European Commission (EC), based on a favorable recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation (ODD) to mavorixafor (X4P-001) for the treatment of WHIM
-
X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences
7/24/2019
Management team is scheduled to present at the 39th Annual Canaccord Genuity Growth Conference, and to conduct one-on-one meetings at the BTIG Biotechnology Conference 2019.
-
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
6/26/2019
X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor (X4P-001) for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease.
-
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
6/12/2019
Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies
-
X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia
5/15/2019
Mavorixafor selected for LLS’s Therapy Acceleration Program® (TAP)
-
X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer
4/24/2019
Dr. Kelley brings more than a decade of experience driving clinical development and global expansion of novel pharmaceutical products at both emerging and established life sciences companies.
-
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
4/12/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock